Navigation Links
Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
Date:3/19/2009

acoeconomics, we believe that a future launch of Gentamicin Implant in the U.S. market represents excellent commercial opportunity."

About Gentamicin Surgical Implant

GENTAMICIN SURGICAL IMPLANT is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold. The product was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and (outside of the U.S.) is indicated as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues. GENTAMICIN SURGICAL IMPLANT is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and there are more than 60 prospective clinical trials and published case reports totaling over 7,500 patients documenting its safety and efficacy over a broad range of orthopedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures. The product is in phase 3 clinical trials in the U.S. for the prevention of surgical site infections and has received FDA fast-track designation for this indication.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll has licensed its US marketing rights to its lead product, CollaRx GENTAMICIN SURGICAL IMPLANT to a division of Baxter International Inc (NYSE: '/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
11. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... Morgan Stanley Global Healthcare Conference on Wednesday, September 10. ... Chief Executive Officer, will provide an update on the ... a.m., Pacific Daylight Time).   A webcast ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
... (Nasdaq: THOR ), a world leader in device-based ... hearts, today announced that it will report its operating results ... 1. The company will hold a conference call ... all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 ...
... 2011 At the 5 ... in Barcelona, Spain (20-22 October 2011),   Merz Pharmaceuticals ... efficacy and safety of   XEOMIN ® ... Dystonia is a particularly debilitating condition ...
Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... that connects the industry’s most notable plastic surgeons ... doctors that write about cutting edge techniques in ... to ensure they contain the most reliable information ... the right cosmetic treatment.     , Cosmetic Town began ...
(Date:8/29/2014)... 29, 2014 DailyGossip.org publishes a review ... absolutely unique method of curing multiple sclerosis in a ... created by Dr. Gary M. Levin, who has become ... to become interested in alternative remedies for a series ... cannot be effective in all cases for the cure ...
(Date:8/29/2014)... August 29, 2014 Dr. Mohebi’s lecture ... who talked about introducing these cutting edge techniques at ... of the FUE Research Committee has allowed him the ... what is possible with modern technology. Dr. Mohebi stated, ... of FUE devices that facilitate extraction and implantation of ...
(Date:8/29/2014)... As reported by CNN.com in the article Prescription ... admitting that you need help for a prescription drug abuse ... the fact that if you simply try to find general ... all of the information that is available online. Although the ... is still possible to get help. The statistics from SAMSHA ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:New Natural Multiple Sclerosis Treatment Review Reveals Gary M. Levin’s Unique Cure 2Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... , WEDNESDAY, Jan. 19 (HealthDay News) -- Along with all ... new research indicates that doing so may reduce your risk ... more than 300,000 people from eight European countries, aged 40 ... into Cancer and Nutrition study and were followed for an ...
... TUESDAY, Jan. 18 (HealthDay News) -- Seniors who want to ... a high-tech assist these days. So can their children ... far from family members. The 1980s-era medical alert pendants ... can,t get up!") are now among a wide array of ...
... A new study at Rochester Institute of Technology indicates ... and sexual abuse, is more than 25 percent higher ... The research also shows a direct correlation between childhood ... post-traumatic stress in adulthood. The study, which was ...
... , A complex sugar may someday become one of the ... disease that has claimed thousands of lives in Haiti since ... University of Central Florida scientists would allow relief workers to ... toxin. In the test, the sugar dextran is coated onto ...
... monogamy is often touted as a way to protect against ... seem to agree on what they decided. And a significant ... would be monogamous weren,t. A new study of 434 ... of couples, only one partner says the couple agreed to ...
... -- Stringent mental health screening before deployment appeared to reduce ... soldiers in Iraq by 78 percent, a new study has ... fell by half, according to the results of the study, ... an upcoming print issue of the American Journal of ...
Cached Medicine News:Health News:Daily Fruit, Veggies May Cut Risk of Heart Disease Death 2Health News:New Devices Help Seniors Stay Longer in Their Own Homes 2Health News:New Devices Help Seniors Stay Longer in Their Own Homes 3Health News:Study: Abuse rates higher among deaf and hard-of-hearing children compared with hearing youths 2Health News:Special sugar, nanoparticles combine to detect cholera toxin 2Health News:Special sugar, nanoparticles combine to detect cholera toxin 3Health News:Young couples can't agree on whether they have agreed to be monogamous 2
BD Phoenix is an automated microbiology system used for identification and susceptibility testing....
ELP 40- 8 Way Head Strip Plate Washer....
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
... High performance plus ... for gentle and efficient ... Washing is performed with ... suspended cells while membrane ...
Medicine Products: